Clinical trials data
Verbal Fluency in cognitive impairment and decline trials: 63 registered studies
Every registered cognitive impairment and decline study on ClinicalTrials.gov that names Verbal Fluency in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cognitive impairment and decline studies name it in an outcome measure
- 63
- Name it in a primary outcome, 56%
- 35 of 63
Tests named in the same studies
- 1
Trail Making Test29 studies, 11 as a primary outcome
- 2
Verbal Learning24 studies, 11 as a primary outcome
- 3
Digit Span Test17 studies, 7 as a primary outcome
- 4
Stroop Color-Word Test13 studies, 6 as a primary outcome
- 5
Symbol Coding13 studies, 3 as a primary outcome
- 6
Picture Naming Test11 studies, 9 as a primary outcome
- 7
Category Fluency10 studies, 6 as a primary outcome
- 8
Clock Drawing Task9 studies, 3 as a primary outcome
- 9
Complex Figure Copy and Recall6 studies, 3 as a primary outcome
- 10
Short Story Recall6 studies, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 2 | 1 |
| 2013 | 4 | 3 |
| 2014 | 0 | 0 |
| 2015 | 2 | 1 |
| 2016 | 4 | 1 |
| 2017 | 4 | 3 |
| 2018 | 8 | 4 |
| 2019 | 6 | 3 |
| 2020 | 5 | 2 |
| 2021 | 4 | 4 |
| 2022 | 3 | 0 |
| 2023 | 8 | 5 |
| 2024 | 2 | 1 |
| 2025 | 5 | 2 |
| 2026 | 4 | 4 |
Phases and study sizes
By phase
- Phase 11 studies, 1 as a primary outcome
- Phase 1/21 studies, 1 as a primary outcome
- Phase 22 studies, 1 as a primary outcome
- Phase 31 studies, 0 as a primary outcome
- Phase 42 studies, 1 as a primary outcome
- Not applicable42 studies, 25 as a primary outcome
- Observational14 studies, 6 as a primary outcome
Participants per study
- Not applicable81 median, 44 to 163
- Observational170 median, 103 to 288
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 42 | 81 | 44 to 163 |
| Observational | 14 | 170 | 103 to 288 |
When cognitive impairment and decline trials measure it
Latest time point of each outcome
- Within a day12 outcomes, 6 as a primary outcome
- Up to 4 weeks3 outcomes, 2 as a primary outcome
- 1 to 3 months12 outcomes, 10 as a primary outcome
- 3 to 6 months14 outcomes, 8 as a primary outcome
- 6 to 12 months9 outcomes, 4 as a primary outcome
- 1 to 2 years5 outcomes, 4 as a primary outcome
- Over 2 years4 outcomes, 0 as a primary outcome
- No duration given4 outcomes, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
59 of the 63 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting12 studies, 7 as a primary outcome
- Not yet recruiting2 studies, 2 as a primary outcome
- Active, not recruiting6 studies, 5 as a primary outcome
- Completed25 studies, 14 as a primary outcome
- Stopped early2 studies, 1 as a primary outcome
- Status unknown16 studies, 6 as a primary outcome
What they test
- Behavioral16 studies, 10 as a primary outcome
- Drug6 studies, 5 as a primary outcome
- Device8 studies, 6 as a primary outcome
- Dietary supplement3 studies, 2 as a primary outcome
- Procedure1 studies, 1 as a primary outcome
- Diagnostic test3 studies, 1 as a primary outcome
- Biological1 studies, 0 as a primary outcome
- Combination product1 studies, 0 as a primary outcome
- Other25 studies, 12 as a primary outcome
- None given4 studies, 1 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States11 studies, 7 as a primary outcome
- China8 studies, 3 as a primary outcome
- Spain8 studies, 6 as a primary outcome
- Italy6 studies, 3 as a primary outcome
- United Kingdom4 studies, 1 as a primary outcome
- Canada3 studies, 1 as a primary outcome
- France3 studies, 1 as a primary outcome
- Mexico3 studies, 3 as a primary outcome
- Netherlands2 studies, 2 as a primary outcome
- Türkiye2 studies, 2 as a primary outcome
- Argentina1 studies, 0 as a primary outcome
- Australia1 studies, 1 as a primary outcome
24 countries in all. A study with sites in several counts in each; 2 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cognitive impairment and decline studies that name Verbal Fluency: 11 of 25, 44%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cognitive impairment and decline studies that name Verbal Fluency | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 1, 4% | 776, 10% |
| Results on ClinicalTrials.gov only | 1, 4% | 1,139, 14% |
| A results paper only | 9, 36% | 1,711, 22% |
| Neither | 14, 56% | 4,327, 54% |
The 63 studies
63 studies match. 35 name Verbal Fluency in a primary outcome. Median size 93 participants. Median time to the primary outcome: 13 weeks.
Loading 63 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 planned to start after 2026.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 2 | 1 |
| 2013 | 4 | 3 |
| 2014 | 0 | 0 |
| 2015 | 2 | 1 |
| 2016 | 4 | 1 |
| 2017 | 4 | 3 |
| 2018 | 8 | 4 |
| 2019 | 6 | 3 |
| 2020 | 5 | 2 |
| 2021 | 4 | 4 |
| 2022 | 3 | 0 |
| 2023 | 8 | 5 |
| 2024 | 2 | 1 |
| 2025 | 5 | 2 |
| 2026 | 4 | 4 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 3, other 60. Interventional 49, observational 14.
As a primary outcomeSecondary or other outcomeVerbal Fluency
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07872189 | Start2027 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants136 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07802392 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants230 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07751510 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants75 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07668440 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants71 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07531888 | Start2026 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07402161 | Start2025 | PhaseObservational | ConditionsCognitive impairment and decline | Participants250 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06927492 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants50 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06836440 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants964 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06832839 | Start2024 | PhaseObservational | ConditionsCognitive impairment and decline | Participants360 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06666088 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants81 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06579664 | Start2025 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants58 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06549517 | Start2023 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants75 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06515106 | Start2023 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06442943 | Start2024 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants128 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06258382 | Start2023 | PhaseObservational | ConditionsCognitive impairment and decline | Participants600 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06227962 | Start2023 | PhaseObservational | ConditionsCognitive impairment and decline | Participants240 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06183788 | Start2023 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants20 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT06013579 | Start2023 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants110 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05856604 | Start2018 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants42 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05854433 | Start2023 | PhaseObservational | ConditionsCognitive impairment and decline | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05504681 | Start2021 | PhaseObservational | ConditionsCognitive impairment and decline | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05485025 | Start2022 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants134 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05232877 | Start2022 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants27 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05199142 | Start2021 | PhasePhase 1 | ConditionsCognitive impairment and decline | Participants5 | Lead sponsorIndustry | StatusStopped early | Library tests named
|
| NCT05166564 | Start2022 | PhaseNot applicable | ConditionsCognitive impairment and decline | Participants105 | Lead sponsorOther | StatusCompleted | Library tests named
|
Questions, answered from the data
How many cognitive impairment and decline trials use Verbal Fluency?
63 registered cognitive impairment and decline studies on ClinicalTrials.gov name it in an outcome measure, 35 of them in a primary outcome: 18% of the condition's 354 studies with a cognitive outcome, against 11% of all of them. It is the 3rd most named test in cognitive impairment and decline trials.
Which tests do cognitive impairment and decline trials use with Verbal Fluency?
The Trail Making Test (29 studies), Verbal Learning (24 studies) and the Digit Span Test (17 studies).
When do cognitive impairment and decline trials measure Verbal Fluency?
Half of the primary outcomes that name Verbal Fluency are measured within 13 weeks of the start, and the middle half from 8 weeks to 6 months. 34 primary outcomes give a duration.
How many completed cognitive impairment and decline trials that use Verbal Fluency have reported results?
11 of the 25 completed studies that name it, 44%, have reported results: 2 posted them on ClinicalTrials.gov, 10 have a results paper linked to the registry record, and 1 did both. The other 14 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run Verbal Fluency in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.